Subscribe
Logo smallSearch
banner

Diagnostic needs of plasmocytic myeloma patients and new approaches to Hodgkin's Lymphoma therapy

MedExpress Team

Piotr Wójcik

Published June 27, 2023 12:58

Diagnostic needs of plasmocytic myeloma patients and new approaches to Hodgkin's Lymphoma therapy - Header image
Interview with Prof. Tomasz Wróble, head of the Department of Hematology, Blood Tumors and Bone Marrow Transplantation of the Faculty of Postgraduate Medical Education of the Piast of Silesia Medical University in Wroclaw.

Plasmocytic myeloma is a rare hematopoietic neoplasm. Its course and prognosis depend on genetic factors, among others. Are high-risk patients currently being properly identified and given access to therapy?

Cytogenetic changes in patients with plasmocytic myeloma are one of the strongest prognostic factors to determine the clinical course of the disease. Patients at high cytogenetic risk are patients whose therapy is a major challenge despite the tremendous advances we have seen in recent years in treatment. Cytogenetic changes are our most important concern.

In predicting the clinical course of myeloma, we rely on the revised International Prognostic Index, which includes questions of cytogenetic changes, among others. A new version of this indicator has recently emerged, which takes into account new cytogenetic changes. This is primarily a matter of the presence of a deletion within chromosome 17, but also changes within chromosome 1. Amplification, or addition, or 1q+ are additional genetic factors that have been included in this indicator. Changes within chromosome...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also